ClinicalTrials.gg
CompletedNCT02775240Updated Jun 3, 2021Results posted

Study of SHP620 (Maribavir) in Healthy Adults

A Phase 1 interventional study of Digoxin and Maribavir in Cytomegalovirus (CMV), sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan). The study will also look at the safety and tolerability when maribavir is coadministered with digoxin and dextromethorphan versus digoxin and dextromethorphan alone.

02

Conditions studied

  • Cytomegalovirus (CMV)

Keywords

  • Maribavir
03

In context

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An understanding, ability, and willingness to fully comply with study procedures and restrictions.
  • Ability to provide written, personally signed, and dated to participate in the study, before completing any study-related procedures.
  • Age 18-50 years, inclusive at the time of consent.
  • Subjects must be willing to consent to and provide blood samples for pharmacogenomics analysis.
  • Willingness to comply with any applicable requirements of the protocol and is:

    1. Male, or
    2. Female of non-
    3. Non-pregnant, non-lactating female
    4. Females must be at least 90 days postpartum or nulliparous.
  • Must be considered "healthy." Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead , hematology, blood chemistry (includes T3, T4, and TSH at screening only), and urinalysis.
  • (BMI) between 18.5 and 30.0 kg/m2 inclusive.
  • is equal to or greater than 12.0g/dL.
  • Ability to swallow a dose of product (which may be multiple tablets at one time or consecutively 1 tablet at a time)

Exclusion criteria

Exclusion Criteria:

  • Subject has a history or a disorder detected during the medical interview/physical examination such as any cardiovascular, broncho-pulmonary, gastrointestinal (eg, inflammatory bowel disease, chronic diarrhea), hepatic, biliary (including gallbladder removal), renal, hematological, endocrine, , neurological, or psychiatric disease (including depression) or any other medical condition that is capable of altering the absorption, metabolism, or elimination of drugs; or of constituting a risk factor when taking the product in the judgment of the investigator.
  • Known or suspected intolerance or to the investigational product(s), closely related compounds, or any of the stated ingredients.
  • Significant illness, as judged by the investigator, within 2 weeks of the first dose of investigational product.
  • Known history of alcohol or other substance abuse within the last year.
  • Donation of blood or blood products (eg, plasma or ) within 60 days prior to receiving the first dose of investigational product.
  • Within 30 days prior to the first dose of investigational product:

    1. Have used an investigational product (if elimination half-life is \<6 days, otherwise 5 half-lives).
    2. Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this study.
    3. Have had any substantial changes in eating habits, as assessed by the investigator.
  • Confirmed systolic blood pressure >139 mmHg or \<89 mmHg and diastolic blood pressure >89 mmHg or \<49 mmHg.
  • Twelve-lead demonstrating >450 msec at screening.
  • A positive screen for alcohol or drugs of abuse at screening or Day -1, Period 1.
  • Male subjects who consume more than 21 units of alcohol per week or 3 units per day; female subjects who consume more than 14 units of alcohol per week or 2 units per day (1 alcohol unit=1 beer or 1 wine [5 oz/150 mL] or 1 liquor [1.5 oz/40 mL] or 0.75 oz alcohol).
  • A positive , surface antibody, or virus antibody screen.
  • Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing products in any form (eg, gum, patch). Ex-users must report that they have stopped using tobacco for at least 30 days prior to receiving the first dose of investigational product.
  • Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6 oz [180 mL] cup of coffee, two 12 oz [360 mL] cans of cola, one 12 oz cup of tea, or three 1 oz [85 g] chocolate bars. Decaffeinated coffee, tea, or cola are not considered to contain caffeine.)
  • Prior screen failure, randomization, participation, or enrollment in this study or prior enrollment in a clinical study investigating maribavir.
  • Current use (defined as use within 14 days prior to the first dose of investigational product) of any medication (including over-the-counter, herbal, or homeopathic preparations [eg, St. John's wort, ginkgo biloba]) with the exception of hormonal replacement therapy and occasional use of ibuprofen and acetaminophen.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Ingestion of known modulators within 7 days of Day 1, Period 1 (includes grapefruit or grapefruit juice, oranges, Seville oranges, apples or apple juice, vegetables from the mustard green family [eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard], charbroiled meats, and products containing these ingredients).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    Digoxin

    On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.

    Drug: Digoxin

  • Experimental
    Maribavir

    On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.

    Drug: Digoxin · Drug: Maribavir · Drug: Dextromethorphan

  • Active comparator
    Dextromethorphan

    On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.

    Drug: Dextromethorphan

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Digoxin

    Cmax is the maximum observed plasma concentration of digoxin.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  2. Maximum Observed Plasma Concentration (Cmax) of Dextromethorphan

    Cmax is the maximum observed plasma concentration of dextromethorphan.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  3. Maximum Observed Plasma Concentration (Cmax) of Dextrorphan

    Cmax is the maximum observed plasma concentration of dextrorphan, the metabolite of dextromethorphan.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  4. Maximum Observed Plasma Concentration (Cmax) of Maribavir

    Cmax is the maximum observed plasma concentration of maribavir.

    Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13

  5. Time to Reach Maximum Plasma Concentration (Tmax) of Digoxin

    Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  6. Time to Reach Maximum Plasma Concentration (Tmax) of Dextromethorphan

    Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  7. Time to Reach Maximum Plasma Concentration (Tmax) of Dextrorphan

    Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  8. Time to Reach Maximum Plasma Concentration (Tmax) of Maribavir

    Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.

    Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13

  9. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin

    AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  10. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextromethorphan

    AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  11. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextrorphan

    AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  12. Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Digoxin

    AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  13. Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextromethorphan

    AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  14. Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextrorphan

    AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  15. Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) for Dextromethorphan Over AUClast for Dextrorphan (AUClast Parent/Metabolite Ratio)

    AUClast parent/metabolite ratio is the ratio of AUClast for dextromethorphan over AUClast for dextrorphan.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  16. Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) for Dextromethorphan Over AUC0-infinity for Dextrorphan (AUC0-infinity Parent/Metabolite Ratio)

    AUC0-infinity parent/metabolite ratio is the ratio of AUC0-infinity for dextromethorphan over AUC0-infinity for dextrorphan.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  17. Area Under the Plasma Concentration Versus Time Curve From Time Zero to the End of the Dosing Interval at Steady-State (AUCtau) of Maribavir

    AUCtau is the area under the plasma concentration versus time curve from the time zero to the end of the dosing interval at steady-state.

    Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13

  18. First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Digoxin

    Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  19. First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextromethorphan

    Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  20. First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextrorphan

    Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  21. Terminal Half-life (t1/2) of Digoxin

    Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  22. Terminal Half-life (t1/2) of Dextromethorphan

    Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  23. Terminal Half-life (t1/2) of Dextrorphan

    Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  24. Terminal Half-life (t1/2) of Maribavir

    Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.

    Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13

  25. Apparent Oral Clearance (CL/F) of Digoxin

    CL/F is equal to dose/AUC0-infinity (dose divided by area under the plasma concentration versus time curve extrapolated to infinity \[AUC0-infinity\]).

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  26. Apparent Oral Clearance (CL/F) of Dextromethorphan

    CL/F is equal to dose/AUC0-infinity (dose divided by area under the plasma concentration versus time curve extrapolated to infinity \[AUC0-infinity\])

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  27. Apparent Oral Clearance (CL/F) of Maribavir

    CL/F is equal to dose/AUCtau (dose divided by area under the curve from time 0 to the end of the dosing interval at steady state \[AUCtau\])

    Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13

  28. Concentration at the End of Dosing Interval (Ctau) of Maribavir

    Ctau is the concentration of maribavir at the end of the dosing interval.

    Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13

  29. Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Digoxin

    Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  30. Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Dextromethorphan

    Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed.

    Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B

  31. Pre-dose Concentration (C0) of Maribavir

    C0 is the lowest concentration reached by a drug before the next dose is administered.

    Time frame: Pre-dose on Day 13

Secondary outcomes

  1. Number of Participants With Study-related Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a participant administered an investigational product (IP) and that did not necessarily have a causal relationship with this treatment. AE was considered to be study-related if there was any valid reason, even if undetermined or untested, for suspecting a possible cause-and-effect relationship between the IP and the occurrence of the AE. An AE was considered a TEAE if it had a start date on or after the first dose of IP or if it had a start date before the date of the first dose of IP, but increased in intensity on or after the date of the first dose of IP. A serious adverse event (SAE) was any untoward medical occurrence (related either to the test product or to the other IP or not) that at any dose resulted in death; was life-threatening; required or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; was a congenital abnormality/birth defect; was an important medical event.

    Time frame: From start of study drug administration up to follow-up (up to 25 days)

  2. Number of Participants With Clinically Significant Changes Reported as TEAE in Physical Examination, Vital Signs, 12-lead ECGs, Hematology, Blood Chemistry and Urinalysis

    Clinical significance of the changes observed in the safety parameters to be reported as TEAE was interpreted by the investigator.

    Time frame: Baseline up to Day 16

07

Results

Posted Jan 16, 2019

Participant flow

The study was conducted in a single center in the United States between 16 August 2016 (first participant first visit) and 31 August 2016 (last participant last visit).

Participant flow — Overall Study
MilestoneTreatment A and B
Started18
Started treatment a18
Started treatment b17
Completed17
Not completed1

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Digoxin

Cmax is the maximum observed plasma concentration of digoxin.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Digoxin
Nanogram per milliliter (ng/mL)Treatment ATreatment B
Maximum Observed Plasma Concentration (Cmax) of Digoxin1.94 (1.60 to 2.36)2.35 (1.98 to 2.80)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 1.248 · 90% CI 1.130 to 1.378Log-transformed Cmax values were compared between treatment regimens using a linear mixed effects model with treatment regimen as fixed effect and participant as random effect.
PrimaryMaximum Observed Plasma Concentration (Cmax) of Dextromethorphan

Cmax is the maximum observed plasma concentration of dextromethorphan.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Dextromethorphan
Nanogram per milliliter (ng/mL)Treatment ATreatment B
Maximum Observed Plasma Concentration (Cmax) of Dextromethorphan1.14 (0.63 to 2.06)1.14 (0.65 to 1.99)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 0.944 · 90% CI 0.778 to 1.144
PrimaryMaximum Observed Plasma Concentration (Cmax) of Dextrorphan

Cmax is the maximum observed plasma concentration of dextrorphan, the metabolite of dextromethorphan.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Dextrorphan
Nanogram per milliliter (ng/mL)Treatment ATreatment B
Maximum Observed Plasma Concentration (Cmax) of Dextrorphan433 (347 to 539)401 (324 to 496)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 0.943 · 90% CI 0.883 to 1.007Log-transformed Cmax values were compared between treatment regimens using a linear mixed effects model with treatment regimen as fixed effect and participant as random effect.
PrimaryMaximum Observed Plasma Concentration (Cmax) of Maribavir

Cmax is the maximum observed plasma concentration of maribavir.

Time frame:
Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Reported as:
Geometric mean · Microgram per milliliter (mcg/mL)
Maximum Observed Plasma Concentration (Cmax) of Maribavir
Microgram per milliliter (mcg/mL)Treatment B
Maximum Observed Plasma Concentration (Cmax) of Maribavir17.6 (15.5 to 19.9)
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Digoxin

Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Median · Hour (h)
Time to Reach Maximum Plasma Concentration (Tmax) of Digoxin
Hour (h)Treatment ATreatment B
Time to Reach Maximum Plasma Concentration (Tmax) of Digoxin1.00 (0.500 to 1.50)1.00 (0.500 to 2.00)
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Dextromethorphan

Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Median · Hour (h)
Time to Reach Maximum Plasma Concentration (Tmax) of Dextromethorphan
Hour (h)Treatment ATreatment B
Time to Reach Maximum Plasma Concentration (Tmax) of Dextromethorphan3.00 (1.50 to 5.00)3.00 (2.00 to 5.00)
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Dextrorphan

Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Median · Hour (h)
Time to Reach Maximum Plasma Concentration (Tmax) of Dextrorphan
Hour (h)Treatment ATreatment B
Time to Reach Maximum Plasma Concentration (Tmax) of Dextrorphan2.00 (1.50 to 3.00)2.00 (1.00 to 4.00)
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Maribavir

Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.

Time frame:
Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Reported as:
Median · Hour (h)
Time to Reach Maximum Plasma Concentration (Tmax) of Maribavir
Hour (h)Treatment B
Time to Reach Maximum Plasma Concentration (Tmax) of Maribavir2.00 (0.500 to 3.00)
PrimaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin

AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin
Nanogram*hour per milliliter (ng*h/mL)Treatment ATreatment B
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin31.6 (26.9 to 37.2)37.3 (32.9 to 42.2)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 1.206 · 90% CI 1.099 to 1.324Log-transformed AUC0-infinity values were compared between treatment regimens using a linear mixed effects model with treatment regimen as fixed effect and participant as random effect.
PrimaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextromethorphan

AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Number · Nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextromethorphan
Nanogram*hour per milliliter (ng*h/mL)Treatment ATreatment B
Participant 1290.74179.19
Participant 228.10NA
Participant 3NA25.14
Participant 4168.6995.95
Participant 548.3341.65
Participant 626.7918.08
PrimaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextrorphan

AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextrorphan
Nanogram*hour per milliliter (ng*h/mL)Treatment ATreatment B
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextrorphan2270 (2050 to 2520)2150 (1940 to 2390)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 0.971 · 90% CI 0.943 to 0.999Log-transformed AUC0-infinity values were compared between treatment regimens using a linear mixed effects model with treatment regimen as fixed effect and participant as random effect.
PrimaryArea Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Digoxin

AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Digoxin
Nanogram*hour per milliliter (ng*h/mL)Treatment ATreatment B
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Digoxin23.0 (19.9 to 26.6)26.7 (24.3 to 29.4)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 1.179 · 90% CI 1.080 to 1.287Log-transformed AUClast values were compared between treatment regimens using a linear mixed effects model with treatment regimen as fixed effect and participant as random effect.
PrimaryArea Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextromethorphan

AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextromethorphan
Nanogram*hour per milliliter (ng*h/mL)Treatment ATreatment B
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextromethorphan7.06 (3.09 to 16.1)6.77 (3.02 to 15.2)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 0.882 · 90% CI 0.696 to 1.118Log-transformed AUClast values were compared between treatment regimens using a linear mixed effects model with treatment regimen as fixed effect and participant as random effect.
PrimaryArea Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextrorphan

AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextrorphan
Nanogram*hour per milliliter (ng*h/mL)Treatment ATreatment B
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextrorphan2200 (1980 to 2450)2110 (1890 to 2360)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 0.973 · 90% CI 0.949 to 0.998Log-transformed AUClast values were compared between treatment regimens using a linear mixed effects model with treatment regimen as fixed effect and participant as random effect.
PrimaryParent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) for Dextromethorphan Over AUClast for Dextrorphan (AUClast Parent/Metabolite Ratio)

AUClast parent/metabolite ratio is the ratio of AUClast for dextromethorphan over AUClast for dextrorphan.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Ratio of AUClast
Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) for Dextromethorphan Over AUClast for Dextrorphan (AUClast Parent/Metabolite Ratio)
Ratio of AUClastTreatment ATreatment B
Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) for Dextromethorphan Over AUClast for Dextrorphan (AUClast Parent/Metabolite Ratio)0.003 (0.001 to 0.008)0.003 (0.001 to 0.008)
Statistical analysis
  • Treatment A vs Treatment B · Linear mixed effects model · Ratio of geometric means: 0.905 · 90% CI 0.721 to 1.138Log-transformed AUClast ratio values were compared between treatment regimens using a linear mixed effects model with treatment regimen as fixed effect and participant as random effect.
PrimaryParent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) for Dextromethorphan Over AUC0-infinity for Dextrorphan (AUC0-infinity Parent/Metabolite Ratio)

AUC0-infinity parent/metabolite ratio is the ratio of AUC0-infinity for dextromethorphan over AUC0-infinity for dextrorphan.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Number · Ratio of AUC0-infinity
Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) for Dextromethorphan Over AUC0-infinity for Dextrorphan (AUC0-infinity Parent/Metabolite Ratio)
Ratio of AUC0-infinityTreatment ATreatment B
Participant 10.1770.127
Participant 20.009NA
Participant 3NA0.014
Participant 40.0960.056
Participant 50.0280.025
Participant 60.0130.008
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time Zero to the End of the Dosing Interval at Steady-State (AUCtau) of Maribavir

AUCtau is the area under the plasma concentration versus time curve from the time zero to the end of the dosing interval at steady-state.

Time frame:
Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Reported as:
Geometric mean · Microgram*hour per milliliter (mcg*h/mL)
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the End of the Dosing Interval at Steady-State (AUCtau) of Maribavir
Microgram*hour per milliliter (mcg*h/mL)Treatment B
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the End of the Dosing Interval at Steady-State (AUCtau) of Maribavir91.5 (79.7 to 105)
PrimaryFirst-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Digoxin

Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Per hour (/h)
First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Digoxin
Per hour (/h)Treatment ATreatment B
First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Digoxin0.02 (0.02 to 0.02)0.02 (0.01 to 0.02)
PrimaryFirst-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextromethorphan

Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Number · Per hour (/h)
First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextromethorphan
Per hour (/h)Treatment ATreatment B
Participant 10.040.04
Participant 20.08NA
Participant 3NA0.11
Participant 40.070.08
Participant 50.100.12
Participant 60.100.10
PrimaryFirst-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextrorphan

Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Per hour (/h)
First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextrorphan
Per hour (/h)Treatment ATreatment B
First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextrorphan0.16 (0.13 to 0.19)0.17 (0.14 to 0.20)
PrimaryTerminal Half-life (t1/2) of Digoxin

Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Hour (h)
Terminal Half-life (t1/2) of Digoxin
Hour (h)Treatment ATreatment B
Terminal Half-life (t1/2) of Digoxin41.5 (38.8 to 44.4)41.8 (36.7 to 47.6)
PrimaryTerminal Half-life (t1/2) of Dextromethorphan

Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Number · Hour (h)
Terminal Half-life (t1/2) of Dextromethorphan
Hour (h)Treatment ATreatment B
Participant 115.8616.17
Participant 29.09NA
Participant 3NA6.43
Participant 49.828.72
Participant 56.865.58
Participant 66.717.03
PrimaryTerminal Half-life (t1/2) of Dextrorphan

Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Hour (h)
Terminal Half-life (t1/2) of Dextrorphan
Hour (h)Treatment ATreatment B
Terminal Half-life (t1/2) of Dextrorphan4.42 (3.63 to 5.37)4.16 (3.55 to 4.87)
PrimaryTerminal Half-life (t1/2) of Maribavir

Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.

Time frame:
Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Reported as:
Geometric mean · Hour (h)
Terminal Half-life (t1/2) of Maribavir
Hour (h)Treatment B
Terminal Half-life (t1/2) of Maribavir4.04 (3.66 to 4.46)
PrimaryApparent Oral Clearance (CL/F) of Digoxin

CL/F is equal to dose/AUC0-infinity (dose divided by area under the plasma concentration versus time curve extrapolated to infinity \[AUC0-infinity\]).

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Oral Clearance (CL/F) of Digoxin
Liter per hour (L/h)Treatment ATreatment B
Apparent Oral Clearance (CL/F) of Digoxin15.8 (13.4 to 18.6)13.4 (11.9 to 15.2)
PrimaryApparent Oral Clearance (CL/F) of Dextromethorphan

CL/F is equal to dose/AUC0-infinity (dose divided by area under the plasma concentration versus time curve extrapolated to infinity \[AUC0-infinity\])

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Number · Liter per hour (L/h)
Apparent Oral Clearance (CL/F) of Dextromethorphan
Liter per hour (L/h)Treatment ATreatment B
Participant 1103.19167.42
Participant 21067.64NA
Participant 3NA1193.51
Participant 4177.84312.65
Participant 5620.71720.23
Participant 61119.901659.07
PrimaryApparent Oral Clearance (CL/F) of Maribavir

CL/F is equal to dose/AUCtau (dose divided by area under the curve from time 0 to the end of the dosing interval at steady state \[AUCtau\])

Time frame:
Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Oral Clearance (CL/F) of Maribavir
Liter per hour (L/h)Treatment B
Apparent Oral Clearance (CL/F) of Maribavir2.19 (1.90 to 2.51)
PrimaryConcentration at the End of Dosing Interval (Ctau) of Maribavir

Ctau is the concentration of maribavir at the end of the dosing interval.

Time frame:
Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Reported as:
Geometric mean · Microgram per milliliter (mcg/mL)
Concentration at the End of Dosing Interval (Ctau) of Maribavir
Microgram per milliliter (mcg/mL)Treatment B
Concentration at the End of Dosing Interval (Ctau) of Maribavir2.13 (1.66 to 2.73)
PrimaryVolume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Digoxin

Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Geometric mean · Liter (L)
Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Digoxin
Liter (L)Treatment ATreatment B
Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Digoxin946 (804 to 1110)809 (723 to 906)
PrimaryVolume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Dextromethorphan

Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed.

Time frame:
Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Reported as:
Number · Liter (L)
Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Dextromethorphan
Liter (L)Treatment ATreatment B
Participant 12360.543904.44
Participant 214008.68NA
Participant 3NA11078.42
Participant 42519.113931.63
Participant 56142.855796.87
Participant 610836.7716835.78
PrimaryPre-dose Concentration (C0) of Maribavir

C0 is the lowest concentration reached by a drug before the next dose is administered.

Time frame:
Pre-dose on Day 13
Reported as:
Geometric mean · Microgram per milliliter (mcg/mL)
Pre-dose Concentration (C0) of Maribavir
Microgram per milliliter (mcg/mL)Treatment B
Pre-dose Concentration (C0) of Maribavir2.64 (1.92 to 3.62)
SecondaryNumber of Participants With Study-related Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant administered an investigational product (IP) and that did not necessarily have a causal relationship with this treatment. AE was considered to be study-related if there was any valid reason, even if undetermined or untested, for suspecting a possible cause-and-effect relationship between the IP and the occurrence of the AE. An AE was considered a TEAE if it had a start date on or after the first dose of IP or if it had a start date before the date of the first dose of IP, but increased in intensity on or after the date of the first dose of IP. A serious adverse event (SAE) was any untoward medical occurrence (related either to the test product or to the other IP or not) that at any dose resulted in death; was life-threatening; required or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; was a congenital abnormality/birth defect; was an important medical event.

Time frame:
From start of study drug administration up to follow-up (up to 25 days)
Reported as:
Count of participants · Participants
Number of Participants With Study-related Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)
ParticipantsTreatment ATreatment B
Study related TEAE412
Serious AE00
Any TEAE412
SecondaryNumber of Participants With Clinically Significant Changes Reported as TEAE in Physical Examination, Vital Signs, 12-lead ECGs, Hematology, Blood Chemistry and Urinalysis

Clinical significance of the changes observed in the safety parameters to be reported as TEAE was interpreted by the investigator.

Time frame:
Baseline up to Day 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes Reported as TEAE in Physical Examination, Vital Signs, 12-lead ECGs, Hematology, Blood Chemistry and Urinalysis
ParticipantsTreatment ATreatment B
Physical examination00
Vital signs00
12-lead ECGs00
Hematology00
Blood Chemistry00
Urinalysis00

Adverse events

Collected over From start of study drug administration up to follow-up (up to 25 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/18 (0%)0/18 (0%)4/18 (22.2%)
Treatment B0/17 (0%)0/17 (0%)12/17 (70.6%)
Most frequent other events
Most frequent other events
EventTreatment ATreatment B
DysgeusiaNervous system disorders0/187/17
HeadacheNervous system disorders2/186/17
Vision blurredEye disorders0/182/17
FlatulenceGastrointestinal disorders2/180/17
Abdominal discomfortGastrointestinal disorders0/181/17
NauseaGastrointestinal disorders0/181/17
Dry eyeEye disorders1/180/17

Baseline characteristics

Safety set consisted of all participants who were administered at least 1 dose of investigational product (maribavir, digoxin, or dextromethorphan) and had at least 1 post-dose safety assessment.

Age, Continuous
Age, Continuous(Year)Treatment A and B
Mean38.1 ± 8.72
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A and B
Female7
Male11
08

Study locations

1 site
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014, United States
09

References and documents

Publications

  • Song IH, Ilic K, Murphy J, Lasseter K, Martin P. Effects of Maribavir on P-Glycoprotein and CYP2D6 in Healthy Volunteers. J Clin Pharmacol. 2020 Jan;60(1):96-106. doi: 10.1002/jcph.1504. Epub 2019 Aug 6. PubMed 31385617 ↗

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Sep 2016, 1 month.

Results were first posted in Jan 2019, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2016
First posted
May 17, 2016
StartActual
Jul 21, 2016
Primary completionActual
Sep 12, 2016
CompletionActual
Sep 12, 2016
Results first posted
Jan 16, 2019
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02775240
Lead sponsor
Shire
Responsible party
Sponsor
First posted
May 17, 2016
Start date
Jul 21, 2016
Primary completion
Sep 12, 2016
Completion
Sep 12, 2016
Results posted
Jan 16, 2019
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Digoxin · Maribavir · Dextromethorphan

Start the discussion